Abilify and Children

Abilify (Aripiprazole) and Children

If your child shows any adverse reactions to Abilify, please contact your health care provider immediately.

Before any prescription medication can be approved for use, it must undergo rigorous studies to prove not only the effectiveness of the product, but also the safety. Abilify for children has undergone many trials to ensure this.

There is much concern when any child is prescribed any form of medication, and this is no different for Abilify in children.

Abilify for children is often used in conjunction with complete treatment programs that include educational, psychological and social interventions.

Before Abilify is prescribed for any children, it is recommended that a thorough diagnostic evaluation has been completed. In addition, the risk associated with medical treatment through the prescription of Abilify and children must be given careful consideration.

Abilify for children is prescribed at much lower doses than for adults.

Abilify for children has been indicated for the following uses, after meeting FDA approval:

1) For the treatment of schizophrenia in children aged 13-17 years (adolescents)

2) Mixed or manic episodes associated with bipolar I disorder, as a monotherapy , in children aged 10-17 (pediatric patients)

3) For treatment of irritability associated with autistic disorder in children aged 6-17 years (pediatrics)

There are important considerations one must understand with regard to Abilify and children. You must consult with your caregiver about these.

There are some warnings associated with Abilify for children as follow:

1) There is an increased risk of suicidal thinking and behaviour for children, young adults and adolescents who are prescribed Abilify for MDD (Major Depressive Disorder) and other psychiatric disorders.

2) Tremor, somnolence and extrapyramidal disorder when Abilify is prescribed for children aged 13-17 (pediatric patients) for schizophrenia

3) Nausea, fatigue, akathisia, salivary hypersecretion, dizziness, blurred vision, somnolence and extrapyramidal disorder in children aged 10-17 years (pediatric patients) with bipolar mania